ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
On April 3, 2017, C. Boyd Clarke, a director and Chairman of the Board of Directors (the “Board”) of Aldeyra Therapeutics, Inc. (the “Company”) notified the Company’s Board that he does not intend to run for re-election at the Company’s 2017 Annual Stockholder Meeting, so that he may devote his efforts to his other commitments. The Company and the Board wish to thank Mr. Clarke for his dedication and service to the Company.
Effective as of the Company’s 2017 Annual Stockholder Meeting, the size of the Board is expected to be reduced from eight to seven members.
About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency. ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Recent Trading Information
ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) closed its last trading session up +0.05 at 5.00 with 21,965 shares trading hands.
